Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBITDA (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed EBITDA for 4 consecutive years, with $101.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 239.53% to $101.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$38.5 million through Dec 2025, up 86.29% year-over-year, with the annual reading at -$38.5 million for FY2025, 86.29% up from the prior year.
  • EBITDA hit $101.3 million in Q4 2025 for Axsome Therapeutics, up from -$46.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $101.3 million in Q4 2025 to a low of -$98.3 million in Q4 2023.
  • Historically, EBITDA has averaged -$45.7 million across 4 years, with a median of -$58.4 million in 2022.
  • Biggest five-year swings in EBITDA: plummeted 955.46% in 2024 and later surged 239.53% in 2025.
  • Year by year, EBITDA stood at -$59.9 million in 2022, then crashed by 64.01% to -$98.3 million in 2023, then grew by 26.11% to -$72.6 million in 2024, then soared by 239.53% to $101.3 million in 2025.
  • Business Quant data shows EBITDA for AXSM at $101.3 million in Q4 2025, -$46.1 million in Q3 2025, and -$36.7 million in Q2 2025.